Rafael Holdings, Inc. RFL
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -8.47%
- 1 year
- -20.00%
- Open
- 1.15
- Prev close
- 1.12
- Mkt cap
- 56.36M
- Vol
- 67.24K
- Avg vol
- 145.08K
- EPS
- -0.58
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.08
- High
- 1.23
- Forward P/E
- 0.00
- Beta
- 1.07
- Short ratio
- 1.80
- Inst. own
- 10.16%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.90
- 200-d avg
- 1.68
- 1y target
- 0.00
News
3 days ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. ("Rafael" or the "Company") (NYSE: RFL). Such investors are advised to…
-
3 days ago benzinga.com
Rafael Holdings Q4 EPS $(0.18) Up From $(0.28) YoY, Sales $244.000K Down From $350.000K YoY
Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.18) per share. This is a 35.71 percent increase over losses of $(0.28) per share from the same period last year. The company reported…
-
3 days ago benzinga.com
Rafael Holdings Files New Drug Application To FDA For Approval Of Remibetadex To Treat Neurovisceral Manifestations Of Niemann-Pick Disease Type C
Rafael Holdings, Inc. (NYSE: RFL) today announced that its subsidiary, Cyclo Therapeutics, LLC, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking…
3 days ago globenewswire.com
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update
NEWARK, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the fourth quarter and full fiscal year 2026 ended July 31, 2026.
3 days ago globenewswire.com
Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type C
NDA supported by the Phase 3 TransportNPC ™ study, data from earlier clinical studies, and an overall survival analysis versus external registry controls
5 days ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Rafael Holdings, Inc. - RFL
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. (“Rafael” or the “Company”) (NYSE: RFL). Such investors are advised…